Susquehanna International Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$396K Buy
57,300
+15,200
+36% +$117K ﹤0.01% 10245
2025
Q4
$371K Sell
42,100
-46,900
-53% -$258K ﹤0.01% 9461
2025
Q3
$444K Sell
89,000
-144,900
-62% -$671K ﹤0.01% 9230
2025
Q2
$1.1M Buy
233,900
+45,800
+24% +$200K ﹤0.01% 7176
2025
Q1
$863K Buy
188,100
+168,400
+855% +$785K ﹤0.01% 7621
2024
Q4
$94.4K Buy
19,700
+7,200
+58% +$34.6K ﹤0.01% 11381
2024
Q3
$58.6K Sell
12,500
-132,100
-91% -$708K ﹤0.01% 11317
2024
Q2
$817K Buy
144,600
+77,700
+116% +$401K ﹤0.01% 7068
2024
Q1
$275K Buy
+66,900
New +$268K ﹤0.01% 9893
2023
Q4
Sell
-10,700
Closed -$46.2K 13379
2023
Q3
$46.2K Buy
+10,700
New +$59.5K ﹤0.01% 11335
2023
Q1
Sell
-37,100
Closed -$274K 13566
2022
Q4
$274K Buy
37,100
+17,300
+87% +$168K ﹤0.01% 9307
2022
Q3
$196K Buy
19,800
+9,600
+94% +$101K ﹤0.01% 10873
2022
Q2
$111K Sell
10,200
-40,700
-80% -$422K ﹤0.01% 11384
2022
Q1
$576K Sell
50,900
-98,900
-66% -$1.3M ﹤0.01% 8609
2021
Q4
$2.35M Buy
149,800
+122,200
+443% +$2.13M ﹤0.01% 5124
2021
Q3
$473K Sell
27,600
-45,400
-62% -$795K ﹤0.01% 9534
2021
Q2
$1.57M Sell
73,000
-28,100
-28% -$503K ﹤0.01% 6521
2021
Q1
$1.52M Buy
101,100
+71,600
+243% +$1.16M ﹤0.01% 6608
2020
Q4
$388K Sell
29,500
-65,300
-69% -$786K ﹤0.01% 8797
2020
Q3
$916K Sell
94,800
-240,700
-72% -$2.57M ﹤0.01% 6323
2020
Q2
$3.84M Buy
335,500
+222,200
+196% +$2.52M ﹤0.01% 3391
2020
Q1
$1.17M Sell
113,300
-12,300
-10% -$153K ﹤0.01% 5032
2019
Q4
$2.06M Buy
125,600
+32,700
+35% +$494K ﹤0.01% 4273
2019
Q3
$1.23M Buy
92,900
+47,400
+104% +$661K ﹤0.01% 5244
2019
Q2
$641K Buy
45,500
+10,000
+28% +$159K ﹤0.01% 6724
2019
Q1
$653K Buy
+35,500
New +$809K ﹤0.01% 5790
2018
Q4
Sell
-11,100
Closed -$255K 10053
2018
Q3
$255K Sell
11,100
-4,400
-28% -$89.8K ﹤0.01% 7787
2018
Q2
$295K Sell
15,500
-81,700
-84% -$1.37M ﹤0.01% 7886
2018
Q1
$1.64M Buy
+97,200
New +$1.63M ﹤0.01% 4296
2017
Q4
Sell
-49,200
Closed -$881K 9960
2017
Q3
$881K Buy
49,200
+26,900
+121% +$450K ﹤0.01% 5500
2017
Q2
$363K Sell
22,300
-10,400
-32% -$150K ﹤0.01% 7229
2017
Q1
$458K Sell
32,700
-228,000
-87% -$3.25M ﹤0.01% 6646
2016
Q4
$4.16M Sell
260,700
-47,800
-15% -$768K ﹤0.01% 2732
2016
Q3
$5.13M Buy
308,500
+257,900
+510% +$3.47M ﹤0.01% 2205
2016
Q2
$566K Sell
50,600
-14,700
-23% -$142K ﹤0.01% 5915
2016
Q1
$546K Sell
65,300
-26,200
-29% -$215K ﹤0.01% 6239
2015
Q4
$852K Buy
91,500
+1,700
+2% +$17K ﹤0.01% 5743
2015
Q3
$1.01M Sell
89,800
-97,800
-52% -$1.2M ﹤0.01% 5723
2015
Q2
$2.38M Buy
187,600
+110,400
+143% +$1.19M ﹤0.01% 4343
2015
Q1
$718K Buy
77,200
+2,400
+3% +$27.1K ﹤0.01% 6409
2014
Q4
$1.07M Sell
74,800
-40,400
-35% -$478K ﹤0.01% 5736
2014
Q3
$1.2M Sell
115,200
-30,600
-21% -$401K ﹤0.01% 5597
2014
Q2
$2.36M Sell
145,800
-118,200
-45% -$1.57M ﹤0.01% 4342
2014
Q1
$4.29M Sell
264,000
-216,300
-45% -$3.08M ﹤0.01% 3101
2013
Q4
$5.96M Buy
480,300
+122,600
+34% +$1.23M ﹤0.01% 2696
2013
Q3
$3.92M Buy
357,700
+180,600
+102% +$1.93M ﹤0.01% 3069
2013
Q2
$1.43M Buy
+177,100
New +$1.19M ﹤0.01% 4422

Other funds holding VNDA

Susquehanna International Group's VNDA Position: Q1 2026 in Review

Susquehanna International Group reduced its Vanda Pharmaceuticals (VNDA) stake by 46% in Q1 2026, selling an estimated $674K and leaving 103,202 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #8771.

Susquehanna International Group first reported a position in VNDA in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.23M in Q1 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Susquehanna International Group held 103,202 shares of Vanda Pharmaceuticals worth $713K as of Q1 2026.
  • Susquehanna International Group sold 87,420 Vanda Pharmaceuticals shares in Q1 2026, an estimated $674K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8771 holding.
  • Susquehanna International Group first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Vanda Pharmaceuticals position peaked at $3.23M in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.